Skip to main content

Drug Interactions between Cytoxan and isavuconazonium

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cycloPHOSphamide isavuconazonium

Applies to: Cytoxan (cyclophosphamide) and isavuconazonium

MONITOR: Coadministration of isavuconazonium sulfate (prodrug of isavuconazole) with drugs that are substrates of CYP450 3A4 and/or 2B6, such as cyclophosphamide, may have variable effects on the plasma concentrations of these drugs. Isavuconazole is a moderate inhibitor of CYP450 3A4 as well as a mild inducer of CYP450 2B6, and the resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.

MANAGEMENT: Until more information is available, caution is advised when isavuconazonium sulfate is used concomitantly with drugs that are substrates of CYP450 3A4 and/or 2B6, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever isavuconazonium sulfate is added to or withdrawn from therapy.

References (2)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. (2015) "Product Information. Cresemba (isavuconazonium)." Astellas Pharma US, Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer